araag2/HINT huggingface dataset:
Clinical trial NCT01746784 (phase 1, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: n6022, normal saline
SMILES: CC1=CC(=CC=C1N1C(CCC(O)=O)=CC=C1C1=CC=C(C=C1)N1C=CN=C1)C(N)=O, O
Eligibility criteria:

        Inclusion Criteria:

          -  Homozygous for F508del-CFTR gene

          -  Sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis

          -  Body weight ≥ 40 kg

          -  FEV1 ≥ 40% predicted

          -  Oxygen saturation ≥ 90% breathing ambient air

          -  Hematology and clinical chemistry of blood and urine results with no clinically
             significant abnormalities that would interfere with the study assessments

          -  Negative pregnancy test for women of child bearing potential

          -  Sexually active subjects of child bearing potential willing to follow contraception
             requirements

        Exclusion Criteria:

          -  Previous enrollment in another cohort for this study.

          -  Any acute infection, including acute upper or lower respiratory infections and
             pulmonary exacerbations that require treatment within 4 weeks of Study Day 1.

          -  Any change in chronic therapies for CF lung disease within 4 weeks of Study Day 1.

          -  Blood hemoglobin <10 g/dL at screening.

          -  Serum albumin <2.5 g/dL at screening.

          -  Abnormal liver function defined as ≥ 3 x upper limit of normal (ULN) in three or more
             of the following: AST, ALT, GGT, ALP, total bilirubin at screening.

          -  History of abnormal renal function (creatinine clearance < 50 mL/min using
             Cockcroft-Gault equation) within a year at screening.

          -  History, including the screening assessment, of ventricular tachycardia or other
             ventricular arrhythmias.

          -  History, including the screening assessment, of prolonged QT and/or QTcF interval (>
             450 msec).

          -  History of solid organ or hematological transplantation.

          -  Intranasal medication changes within 14 days prior to Study Day 1

          -  Required Use of continuous (24 hr/d) or nocturnal supplemental oxygen.

          -  Concomitant use of any inhibitors or inducers of CYP3A4.
Clinical trial NCT01799161 (phase 1, status: withdrawn)
Conditions: non-small cell lung cancer, non-small-cell lung carcinoma, lung cancer, nsclc
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, D02.20, D02.21, D02.22, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: theophylline
SMILES: CN1C2=C(NC=N2)C(=O)N(C)C1=O
Reason stopped: 
    insufficient funding
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed NSCLC (squamous, adeno-, large cell anaplastic,
             bronchoalveolar, and non-small cell carcinoma NOS): stage IIIB with malignant pleural
             effusion, stage IV, or recurrent disease.

          -  At least one site of measurable disease.

          -  Brain metastasis if present and treated must be stable by CT scan or MRI for at least
             4 weeks after treatment.

          -  Patient must have received and failed at least one line of palliative therapy
             (chemotherapy or biological therapy)

          -  Age >= 18 years.

          -  ECOG performance status 0-2.

          -  Life expectancy >= 3 months.

          -  Laboratory parameters

               -  Hemoglobin levels >= 10.0 (transfusions allowed if necessary).

               -  ANC >= 1,500.

               -  Platelets >= 100k.

               -  Creatinine clearance >= 50 ml/min.

               -  Total and direct bilirubin: < 3.0 x upper institution limit for normal.

               -  Liver function tests: AST, ALT, and AlkP < 3.0 x upper institution limit for
                  normal.

               -  Signed informed consent.

        Exclusion Criteria:

          -  Active or symptomatic cardiac disease such as congestive heart failure, angina
             pectoris or recent myocardial infarction. Patients with history of these conditions
             who are stable taking cardiac medications will also be excluded.

          -  Pregnant or lactating women (negative test for pregnancy is required of women of
             childbearing potential).

          -  Known HIV infection.

          -  Uncontrolled or untreated brain or spinal cord metastases.

          -  Active infection.

          -  Concomitant steroid or other immunosuppressive therapy.

          -  Other active malignancies present within the past three years, except for basal and/or
             squamous cell carcinoma(s) or in situ cervical cancer.

          -  Meningeal carcinomatosis.

          -  Chemotherapy, radiation therapy, or other anti-tumor therapy during the last three
             weeks.

          -  Immune deficiency syndromes, including the following: rheumatoid arthritis, systemic
             lupus erythematousus, Sjogren's disease, sarcoidosis, vasculitis, polymyositis,
             glomerulonephritis.

          -  Compromised lung function:

               -  FeV1 < 30% of the predicted value, or

               -  DLCO < 30% of the predicted value, or

               -  PCO2 > 45 mmHg.
Clinical trial NCT01836289 (phase 1/phase 2, status: withdrawn)
Conditions: crohn's disease, crohn disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919, K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: high-dose cyclophosphamide
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Reason stopped: 
    too difficult to recruit given new crohn's medications approved
  
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ 18 years of age, males and females will be eligible

          -  Moderate to severe Crohn's Disease (CD) with CDAI > 220, in addition to evidence of
             ulceration on ileocolonoscopy or active disease on small bowel imaging (in patients
             with an ostomy, CDAI criteria do not apply)

          -  Disease progression (primary or secondary non-responder, or reaction to) to at least
             one anti-tumor necrosis factor (TNF) agent (infliximab, adalimumab, certolizumab
             pegol), and additionally had disease progression despite one of the following
             immunosuppressant drugs: azathioprine, 6-mercaptopurine, methotrexate, cyclosporine,
             natalizumab, vedolizumab

          -  Willingness to participate in a clinical trial

          -  Approval by Enrollment Panel, who will collectively decide on the appropriateness of
             possible study study participants

        Exclusion Criteria:

          -  Pregnant or nursing women

          -  Sexually active men and women who do not agree to use effective means of birth control
             during treatment period

          -  Evidence of primarily fibrostenosing disease without active inflammatory disease on
             disease staging

          -  Co-morbid conditions including cardiac disease with an ejection fraction of < 45%,
             chronic renal failure with serum creatinine > 2.0, liver disease with total bilirubin
             > 2.0, (excluding hyperbilirubinemia secondary to Gilbert's disease) or transaminitis
             > 3x upper limit of normal.

          -  History of serious allergic reaction to cyclophosphamide

          -  History of malignancy in the last 5 years (excluding non-melanomatous skin cancers)

          -  Patients who are pre-terminal

          -  Toxic megacolon

          -  Active infection

          -  White blood cell count < 3000 cells/ul, platelets < 100K / ul, hemoglobin < 10.0 g/dL

          -  Any use of thiopurines, methotrexate or anti-TNF agents in the previous four weeks
             prior to treatment
Clinical trial NCT01940133 (phase 1, status: completed)
Conditions: advanced solid tumors
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: pqr309
SMILES: CN1N=NC2=C(N=CN2C1=O)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of advanced solid tumor for which
             no therapy of proven efficacy is available.

          -  Age ≥ 18

          -  Evidence of tumor progression with measurable or evaluable disease.

          -  Use of adequate contraceptive measures for male patients.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Concomitant anticancer therapy (e.g., chemotherapy, radiotherapy, hormonal,
             immunotherapy, biological response modifier, signal transduction inhibitors)

          -  Patients with a history of myocardial infarction or coronary artery bypass within the
             last 3 years.

          -  Patients with severe/unstable angina, coronary/peripheral arterial bypass, symptomatic
             congestive heart failure NYHA Class 3 or 4, hypertension BP>150/100mmHg.

          -  Pre-diagnosed diabetes mellitus.

          -  Fasting glucose > 7.0 mmol/L or HbA1c > 6%.
Clinical trial NCT01949532 (phase 1, status: completed)
Conditions: relapsed multiple myeloma, end-stage renal disease
ICD codes: G35, M15.3, M67.49, M89.09, M89.59, M94.29, Q78.6, N18.6, I12.0, I13.11, I13.2
Drugs: carfilzomib
SMILES: CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
Eligibility criteria:

        Key Inclusion Criteria:

          1. Relapsed multiple myeloma

          2. Evaluable disease (serum protein electrophoresis [SPEP]/urine protein electrophoresis
             [UPEP]/serum free light chain [SFLC] criteria)

          3. Received at least 1 prior treatment regimen or line of therapy for multiple myeloma

          4. End-stage renal disease (ESRD) on hemodialysis or CrCl ≥ 75 mL/min

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2

          6. Adequate organ and bone marrow function

          7. Active congestive heart failure (New York Heart Association [NYHA] Class III to IV),
             symptomatic ischemia, conduction abnormalities uncontrolled by conventional
             intervention or myocardial infarction within the protocol-specified period prior to
             enrollment

        Key Exclusion Criteria:

          1. Immunoglobulin M (IgM) multiple myeloma

          2. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
             skin changes)

          3. Waldenström Macroglobulinemia

          4. Active congestive heart failure (NYHA Class III-IV) ischemia, conduction abnormalities

          5. Known human immunodeficiency virus (HIV), recent hepatitis B virus (HBV), hepatitis C
             virus (HCV)

          6. Myelodysplastic Syndrome

          7. Contraindication to test article, constituents, or required concomitant medications

          8. Other investigational drugs
Clinical trial NCT01954732 (phase 1, status: withdrawn)
Conditions: stage ia pancreatic cancer, stage ib pancreatic cancer, stage iia pancreatic cancer, stage iib pancreatic cancer
ICD codes: C25.3, C25.3, C25.3, C25.3
Drugs: metformin hydrochloride
SMILES: CN(C)C(=N)NC(N)=N
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed resectable pancreatic
             carcinoma; patients with pancreatic neuroendocrine tumors are not eligible

          -  Patients must be previously untreated with chemotherapy or radiation therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2

          -  Patients must have surgical resection of the pancreas planned, with enrollment at
             least 7 days prior to surgery; patients with surgery scheduled > 15 days will not be
             excluded

          -  Hemoglobin (Hg)A1C must be below 7%

          -  Total bilirubin less than 1.5 X institutional upper limit of normal

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =<
             2.5 X institutional upper limit of normal

          -  Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X
             institutional upper limit of normal

          -  Serum creatinine within normal institutional limits

          -  Alkaline phosphatase < 1.5 X institutional upper limit of normal

          -  Subjects must have the ability to understand and be willing to provide written
             informed consent

        Exclusion Criteria:

          -  History of metformin use in the previous 3 months

          -  Treatment with neoadjuvant chemotherapy or radiation therapy

          -  History of allergic reactions attributed to metformin

          -  Patients with uncontrolled intercurrent illness including, but not limited to ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Metabolic acidosis, acute or chronic, including ketoacidosis

          -  Metastatic disease
Clinical trial NCT01965600 (phase 1, status: terminated)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: pf-06282999, placebo, pf-06282999, placebo
SMILES: COC1=CC=C(Cl)C=C1C1=CC(=O)NC(=S)N1CC(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(Cl)C=C1C1=CC(=O)NC(=S)N1CC(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy men or women (non-childbearing potential) between the ages of 18-40 years.

          -  Body Mass Index (BMI) 18-30 kg/m2 and a total body weight >50 kg (110 lbs).

        Exclusion Criteria:

          -  History or evidence of habitual use of tobacco- or nicotine-containing products within
             3 months of screening.

          -  History of frequent headaches or migraines (>3 per month), or headaches from an
             absence of caffeine.

          -  Caffeine consumption in excess of 3 cups per day.

          -  Subjects who have experienced cold/flu symptoms (ie, runny nose, cough, and/or fever)
             within 2 weeks of the first administration of study drug/placebo of each period.

          -  History of recurrent or chronic infections of any type such as tuberculosis,
             sinusitis, urinary tract infection, respiratory tract or dental (abscess) infection,
             etc. Also excluded are subjects with recurrent oral or genital herpes, recurrent
             herpes zoster, or any infection otherwise judged by the investigator to have the
             potential for worsening if enrolled in this study.

          -  Treatment with LPS in the past 12 months and/or a history of an allergic type reaction
             or known hypersensitivity to endotoxin at any time.
Clinical trial NCT01966731 (phase 1/phase 2, status: active, not recruiting)
Conditions: sickle cell disease
ICD codes: D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, D57.218
Drugs: hydroxyurea
SMILES: NC(=O)NO
Eligibility criteria:

        Inclusion Criteria

          1. Pediatric patients with documented sickle cell anemia (typically HbSS supported by
             hemoglobin electrophoresis, complete blood count, and peripheral blood smear)

          2. Age range of 1.00-9.99 years, inclusive, at the time of enrollment

          3. Weight at least 10.0 kg at the time of enrollment

          4. Parent or guardian willing and able to provide written informed consent, with child's
             verbal assent as per local IRB/Ethics Board requirements

          5. Willingness to comply with all study-related treatments, evaluations, and follow-up

        Exclusion Criteria

          1. Known medical condition making participation ill-advised, (e.g., acute or chronic
             infectious disease, HIV, or malignancy)

          2. Acute or chronic severe malnutrition determined by impaired growth parameters as
             defined by WHO (weight for length/height or weight-for-length/height >3 z-scores below
             the median WHO growth standards, as defined in Appendix I)

          3. Pre-existing severe hematological toxicity (temporary exclusions)

               1. Anemia: Hb <4.0 gm/dL

               2. Anemia: Hb <6.0 gm/dL with ARC <100 x 109/L

               3. Reticulocytopenia: ARC <80 x 109/L with Hb <7.0 gm/dL

               4. Thrombocytopenia: Platelets <80 x 109/L

               5. Neutropenia: ANC <1.0 x 109/L

          4. Blood transfusion within 60 days before enrollment (temporary exclusion)

          5. Hydroxyurea use within 6 months before enrollment
Clinical trial NCT01980667 (phase 1, status: completed)
Conditions: advanced solid tumors
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: lurbinectedin (pm01183), cisplatin
SMILES: COC1=CC=C2NC3=C(CCN[C@]33CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](CC7=C6C(O)=C(OC)C(C)=C7)[C@H](O)N5[C@@H](COC3=O)C3=C4C(OC(C)=O)=C(C)C4=C3OCO4)C2=C1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Voluntarily signed written informed consent

          -  Age ≥ 18 years old

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 1.

          -  Life expectancy ≥ 3 months.

          -  Patients with confirmed diagnosis of advanced solid tumors.

          -  Patients may have received ≤ 2 chemotherapy-containing lines in the advanced setting.

          -  Adequate bone marrow, renal, hepatic, and metabolic function (assessed ≤ seven days
             before inclusion in the study)

          -  Recovery or stabilization to grade ≤ 1 from any adverse event derived from previous
             treatment (up to grade 2 alopecia or asthenia/fatigue are allowed).

          -  No clinically significant changes in ECG.

          -  At least four weeks since the last monoclonal antibody containing therapy or
             definitive radiotherapy (RT)

          -  At least two weeks since the last biological/investigational single-agent therapy
             (excluding MAbs) and/or palliative RT (≤10 fractions or ≤30 Gy total dose)

          -  Fertil women must have pregnancy excluded by appropriate testing before study entry

        Exclusion Criteria:

          -  Prior treatment with PM01183 or trabectedin.

          -  Concomitant diseases/conditions:

               -  History within the last year or presence of unstable angina, myocardial
                  infarction, congestive heart failure, or clinically relevant valvular heart
                  disease or symptomatic arrhythmia or any asymptomatic ventricular arrhythmia
                  requiring ongoing treatment.

               -  Ongoing, non-neoplastic, chronically active liver disease of any origin.

               -  Active infection.

               -  Patients who are requiring any ongoing oxygen support.

               -  Known human immunodeficiency virus (HIV) infection.

               -  Any other major illness.

          -  Symptomatic or corticosteroid-requiring brain metastases or leptomeningeal disease
             involvement. Patients with asymptomatic documented stable brain metastases not
             requiring corticosteroids during the last three months are allowed.

          -  Peripheral sensory/motor neuropathy grade >1. Hearing impairment grade >1.

          -  Fertile men or women not using an effective method of contraception.

          -  History of bone marrow or stem cell transplantation

          -  Radiotherapye to >35% of the bone marrow.
Clinical trial NCT01981499 (phase 1, status: terminated)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: pf-05180999, placebo, 120 mg mr pf-05180999, 360 mg mr pf-05180999, 10 mg cetirizine, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the trial was prematurely terminated on 01april2014 due to safety concerns.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male subjects between the ages of 18 and 55 years

          -  No history of clinically-relevant atopic or dermatological disease

          -  Positive reaction to intradermal injection of histamine

        Exclusion Criteria:

          -  Subjects with screening laboratory test results that deviate from the upper and/or
             lower limits of the reference or acceptable range. The exception is that all liver
             function tests must not exceed the upper limit of normal.

          -  Subjects with evidence of, or history of, hepatic disorder, including acute or chronic
             hepatitis B or hepatitis C

          -  Intolerance to intradermal histamine injection.

          -  Subjects with dark skin (Part B only).
Clinical trial NCT01986751 (phase 1/phase 2, status: terminated)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: clonidine, ropivacaine
SMILES: ClC1=CC=CC(Cl)=C1NC1=NCCN1, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Reason stopped: 
    failure to enroll
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patient undergoing foot or ankle surgery with popliteal nerve block planned for
             postoperative analgesia.

          2. Adult, 19 years of age and older.

          3. Subject classified as American Society of Anesthesiology (ASA) class 1, 2, or 3. The
             ASA defines these statuses as follows: 1-A normal healthy patient. 2-A patient with
             mild systemic disease. 3-A patient with severe systemic disease.

             -

        Exclusion Criteria:

          1. Any subject not classified as an ASA 1, 2, or 3.

          2. Allergy/intolerance to local anesthetic, clonidine, and/or oxycodone.

          3. Subject with a history of continuous opioid use for greater than one month prior to
             surgery.

          4. Pre-existing neurologic deficit in lower extremity (surgical site).

          5. Clinically significant coagulopathy (hemophilia, von Willebrand disease).

          6. Patients who fail to follow the UAB Department of Anesthesiology Algorithm for the
             Preoperative Management of an Angiotensin Converting Enzyme Inhibitor (ACEI) or an
             Angiotensin Receptor Blocker (ARB). A copy of the algorithm can be found in Appendix
             1. -